De novo Synthesis of 2-phenylethanol from Glucose by Metabolically Engineered Escherichia coli
Journal of Industrial Microbiology and Biotechnology · 2023
DOI: 10.1093/jimb/kuac026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Industrial Microbiology and Biotechnology, 2023. Verfasst von Guanglu Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Food and Bioengineering/Collaborative Innovation Center for Food Production and Safety, Zhengzhou University of Light Industry, Zhengzhou, …. Hauptthemen laut MEDLINE: Phenylethyl Alcohol, Escherichia coli Proteins. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Department of Henan Province.
Abstract (Originalsprache)
2-Phenylethanol (2- PE) is an aromatic alcohol with wide applications, but there is still no efficient microbial cell factory for 2-PE based on Escherichia coli. In this study, we constructed a metabolically engineered E. coli capable of de novo synthesis of 2-PE from glucose. Firstly, the heterologous styrene-derived and Ehrlich pathways were individually constructed in an L-Phe producer. The results showed that the Ehrlich pathway was better suited to the host than the styrene-derived pathway, resulting in a higher 2-PE titer of ∼0.76 ± 0.02 g/L after 72 h of shake flask fermentation. Furthermore, the phenylacetic acid synthase encoded by feaB was deleted to decrease the consumption of 2-phenylacetaldehyde, and the 2-PE titer increased to 1.75 ± 0.08 g/L. As phosphoenolpyruvate (PEP) is an important precursor for L-Phe synthesis, both the crr and pykF genes were knocked out, leading to ∼35% increase of the 2-PE titer, which reached 2.36 ± 0.06 g/L. Finally, a plasmid-free engineered strain was constructed based on the Ehrlich pathway by integrating multiple ARO10 cassettes (encoding phenylpyruvate decarboxylases) and overexpressing the yjgB gene. The engineered strain produced 2.28 ± 0.20 g/L of 2-PE with a yield of 0.076 g/g glucose and productivity of 0.048 g/L/h. To our best knowledge, this is the highest titer and productivity ever reported for the de novo synthesis of 2-PE in E. coli. In a 5-L fermenter, the 2-PE titer reached 2.15 g/L after 32 h of fermentation, suggesting that the strain has the potential to efficiently produce higher 2-PE titers following further fermentation optimization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Food and Bioengineering/Collaborative Innovation Center for Food Production and Safety, Zhengzhou University of Light Industry, Zhengzhou, Henan 450000, People's Republic of China.
- Technology Center, China Tobacco Henan Industrial Co. Ltd. Zhengzhou, Henan 450000, People's Republic of China.
- Jiangsu Key Laboratory of Chiral Pharmaceuticals Biosynthesis, College of Pharmaceutical Chemistry & Chemical Engineering, Taizhou University, Taizhou, Jiangsu 225300, People's Republic of China.
ORCID-Profile: Guanglu Wang, Xuepeng Yang
Förderung
- National Natural Science Foundation of China
- Science and Technology Department of Henan Province
Zitieren
APA
Wang, G., Wang, M., Yang, J., Li, Q., Zhu, N., Liu, L., Hu, X., & Yang, X. (2023). De novo Synthesis of 2-phenylethanol from Glucose by Metabolically Engineered Escherichia coli. Journal of Industrial Microbiology and Biotechnology. https://doi.org/10.1093/jimb/kuac026
Vancouver
Wang G, Wang M, Yang J, Li Q, Zhu N, Liu L, et al. De novo Synthesis of 2-phenylethanol from Glucose by Metabolically Engineered Escherichia coli. Journal of Industrial Microbiology and Biotechnology. 2023. doi:10.1093/jimb/kuac026
BibTeX
@article{Wang2023,
author = {Wang, Guanglu and Wang, Mengyuan and Yang, Jinchu and Li, Qian and Zhu, Nianqing and Liu, Lanxi and Hu, Xianmei and Yang, Xuepeng},
title = {De novo Synthesis of 2-phenylethanol from Glucose by Metabolically Engineered Escherichia coli},
journal = {Journal of Industrial Microbiology and Biotechnology},
year = {2023},
doi = {10.1093/jimb/kuac026}
}
EUVIMED